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Stem cells are the seeds of tissue repair and regeneration and a promising source for novel therapies.
However, apart from hematopoietic stem cell (HSC) transplantation, essentially all other stem cell treatments
remain experimental. High hopes have inspired numerous clinical trials, but it has been difficult to obtain
unequivocal evidence for robust clinical benefit. In recent years, unproven therapies have been widely prac-
ticed outside the standard clinical trial network, threatening the cause of legitimate clinical investigation.
Numerous challenges and technical barriers must be overcome before novel stem cell therapies can achieve
meaningful clinical impact.Cell Therapeutics: The Current Standard of Care
In the twentieth century small molecule and protein drugs proved
remarkably successful in restoringhealth andextending life span,
but in the twenty-first century our aging population will face
an increasing burden of organ failure and neurodegenerative
disease. Such conditions are unlikely to be cured by drugs alone
and instead call for restoration of tissue function through novel
therapeutic approaches. Transplantation of whole organs—
heart, lung, liver, kidney, small bowel, and pancreas—has
become routine in modern medicine and has saved countless
lives, while grafts of the skin and cornea for burns or ocular injury
and transfusions of red blood cells and platelets for disease-
related or chemotherapy-induced cytopenias are likewise widely
employed tissue andcell therapies. However, current therapeutic
strategies either are limitedbydonor availability and immunologic
barriers or pertain to only a minor range of conditions. For the
many diseases and disorders of aging for which there is no
cure, innovative applications of tissue engineering and novel
cell therapies derived from pluripotent and tissue-restricted
stem cells represent major frontiers for the future.
Hematopoietic stem cells (HSCs), the therapeutic constituents
of whole bone marrow and umbilical cord blood, have been the
most widely employed stem cell therapy. When successful, HSC
transplantation can be curative for scores of genetic blood
disorders like thalassemia and immune deficiency and for malig-
nancies like leukemia and lymphoma. HSC transplantation is
undoubtedly the most successful application of stem cells in
medicine, yet for many conditions success rates remain frustrat-
ingly low and morbidity and mortality unacceptably high. The
need for precise molecular matching of donor and recipient
means that many patients lack a suitable donor, either within
their own family or in the public at large, even when databases
list many millions of potential unrelated donors. When a match
can be found, minor mismatches between donor and recipient
frequently incite graft versus host disease (GVHD), an attack of
the donor immune effector T cells against host tissues that
results in skin rash, mucositis, diarrhea, and liver and lung
destruction. GVHD is a major cause of treatment associated740 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.morbidity and mortality. Finally, grafts can fail, and disease can
relapse. Although it is difficult to give a precise figure for the over-
all success rate for HSC transplantation, even an optimist would
acknowledge that some 50%of patients are left without a cure or
with a permanent disability. Thus, even our most successful form
of stem cell therapy remains a heroic effort, reserved only for the
sickest patients who have no better alternative.
Lessons from the Historical Development of HSC
Transplantation
The evolution of HSC transplantation from its experimental
origins to its acceptance as a standard of care in medicine is
a tale that is both inspiring and cautionary. E. Donnall Thomas
and colleagues were the first to perform marrow transplantation
for otherwise fatal leukemia in the 1950s (Thomas et al., 1957).
The rationale was predicated upon the known capacity for radi-
ation to suppress leukemic hematopoiesis and studies demon-
strating that injections of marrow rescued mice from otherwise
lethal radiation exposure (Jacobson et al., 1951; Lorenz et al.,
1951). Thomas wrote in a memoir in 2005, ‘‘These patients
inspired us to speculate that it might be possible to destroy
leukemic cells and normal marrow by lethal whole body irradia-
tion, with reconstitution of marrow by marrow transplantation.’’
Arguably, the first studies in humans were founded upon rather
minimal evidence of efficacy in rodent models, and Thomas
further noted, ‘‘We recognized that it would be important to do
similar studies in an animal model . [and] decided to move
forward with studies of man and dog at the same time’’ (Thomas,
2005). Indeed, Thomas and colleagues suffered considerable
failure in preclinical canine models and witnessed the deaths
of many scores of patients, which prompted great skepticism
about whether the human experiments should continue. Never-
theless, Thomas and his intrepid team of investigators forged
ahead. It took almost two decades before advances in research
on tissue matching to define compatible donor-recipient pairs,
and improved treatment of graft versus host disease and the
infectious complications of marrow transplant allowed marrow
transplantation to achieve consistent success in the late 1970s.
Figure 1. Clinical Trials of Major Stem Cell Types
Pie chart indicating the relative numbers of open trials testing clinical inter-
ventions for hematopoietic, neural, mesenchymal, adipose, and embryonic
stem cells, as listed on the U.S. NIH website clinicaltrials.gov.
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history of HSC transplantation. First, the risk of the intervention
should be commensurate with the severity of the underlying
condition to be treated. The aggressively malignant nature of
the conditions being treated—fatal leukemia and marrow apla-
sia—meant that the first practitioners of marrow transplantation
were justified and even compelled to attempt heroic and poten-
tially highly toxic interventions for invariably fatal diseases.
Second, although human biology is only partially predictable
from animal models, preclinical animal models remain a key
element in the scientific development of novel therapies. At the
beginning of human marrow transplantation, it was understood
that identical twins accepted skin and solid organ grafts, but
only a minority of the time did siblings. Experiments in themurine
and canine marrow transplantation models reflected similar
transplantation barriers. Notwithstanding these sobering limita-
tions, the early practice of marrow transplant in patients pro-
ceeded despite a lack of robust evidence in animal models for
graft acceptance between unrelated individuals. Only later
were methods for lymphocyte matching developed (the ante-
cedent to HLA typing), which was the key development in
advancing the success ofmarrow transplantation. Finally, impor-
tant and fundamental insights into therapeuticmechanismswere
required before the eventual success of clinical translation of
HSC transplantation therapies.
With the benefit of hindsight, one could argue that the earliest
human transplants were premature and doomed to fail. One
might question whether a therapy as toxic as marrow transplant,
with so little evidence for success in animal models prior to
testing in humans, could emerge in the current era. Under
today’s more rigorous regulatory climate, institutional review
boards weigh risks and potential benefit on behalf of patients,
insist on an impartial process of informed consent to minimize
misconceptions about therapeutic potential, and monitor
adverse events in the course of clinical trials. Indeed, one might
reasonably conclude that today’s IRBs might not have approved
the early studies of Thomas and colleagues, but if they had,
would have interceded to stop the experiments when the high
incidence of treatment-related mortality became apparent.
The conjecture that modern-day IRBs might not approve the
early experiments in HSC transplant does not imply that HSC
transplant would not emerge under the current regulatory
climate. On the contrary, I believe that bone marrow transplant
could be developed within today’s environment of strict clinical
research regulation, although by a more conservative path that
would spare considerable patient morbidity and mortality. As
we learned from premature attempts at gene therapy in the early
1990s, new therapeutic technologies require considerable
understanding of fundamental mechanisms before they can be
delivered with confidence. Indeed, roughly 70% of early phase
clinical trials of pharmaceuticals fail and over 50% at phase III
(Ledford, 2011), and thus it stands to reason that significant
resources are squandered because of the imprecision of early
stage clinical research. Yet, especially with novel technologies,
clinical experimentation proceeds energetically, because hope
triumphs over experience. From this author’s perspective,
a conservative approach to clinical translation of stem cell ther-
apies is warranted at this time, not because stem cell treatments
are excessively risky (though some may yet prove to be), butrather because our understanding of the mechanisms by which
stem cells might prove useful, and in which diseases, remains
primitive. In a climate where government and philanthropic funds
for fundamental research are increasingly scarce, and invest-
ment capital from the private sector for biotechnology has dried
up, purely empirical attempts at stem cell therapy are difficult to
justify, given the high probability of failure. In a 1995 report
assessing the investment in gene therapy by the U.S. National
Institutes of Health, a panel chaired by Stuart Orkin and Arno
Motulsky recommended ‘‘increased emphasis on research
dealing with the mechanisms of disease pathogenesis, further
development of animal models of disease, enhanced use of
preclinical gene therapy approaches in these models, and
greater study of stem cell biology in diverse organ systems’’
(http://oba.od.nih.gov/oba/rac/panelrep.pdf). Similar recom-
mendations regarding the need for proper investments in funda-
mental aspects of stem cell therapeutics seems warranted and
prudent at this time.
Stem Cell Therapeutics: Frontline Clinical Trials
and Medical Innovations
A search of the Unites States government-sponsored website
www.clinicaltrials.gov with the term ‘‘stem cells’’ lists over
4,000 past, current, and anticipated trials, with over 1,750 now
open (Figure 1). The vast majority of open trials aim to build
upon decades of research and clinical experience in hematopoi-
etic transplantation (>1,200), and include strategies to expand
the suboptimal dose of HSCs within umbilical cord blood, to
complement gene defects in HSCs through viral transgene
delivery (‘‘gene therapy’’), and to engineer T cells to attackmalig-
nancy via adoptive immunotherapy. Despite the relatively primi-
tive understanding of therapeutic mechanisms for other stem
cells, hundreds more trials are testing mesenchymal (115),
adipose-derived (36), and neural stem cells (280), sometimes
in quite bold and unconventional ways that bear little resem-
blance to the known differentiation potential or modes of tissueCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 741
Figure 2. Worldwide Experimental Trials of Stem Cell-Based Therapies
World map showing locations of open, closed, and pending clinical trials of stem cell-based interventions as listed on clinicaltrials.gov. The relative numbers of
trials performed outside of the U.S. may indeed be markedly understated because of reporting bias at the U.S. government clinical trials website.
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cells. As of this writing, three trials pertain to products derived
from ESCs. A wide array of stem cell studies are being carried
out on a global basis on all continents, suggesting widespread
clinical interest (Figure 2).
Mesenchymal stem cells (MSCs) are defined by their fibro-
blast-like morphology, adherence to plastic, expression of
a specific set of surface antigens (CD105+, CD90+, CD73+),
and capacity for osteogenic, chondrogenic, and adipogenic
fates in vitro. MSCs are most often derived from bone marrow
but can also be isolated from adipose tissue; adipose-derived
stem cells may also consist of pericytes or endothelial progeni-
tors that may differ somewhat in their properties from MSCs.
Easy access to large quantities is an advantage for adipose-
derived stem cells, which are being tested for soft-tissue repair
and regeneration (Tobita et al., 2011). Both autologous (self)
and allogeneic (foreign) MSCs are being tested in vivo to
enhance healing that reflects their in vitro potential to form
bone or cartilage, as in bone fracture and joint cartilage repair
(Griffin et al., 2011). Although such studies are founded on strong
preclinical evidence and sound scientific and clinical hypoth-
eses, evidence for robust clinical efficacy of MSCs for ortho-
pedic indications has been challenging to confirm, and to date
no therapy based on MSCs has yet won approval by the U.S.
Food and Drug Administration (FDA). The difficulty in proving
the efficacy of regenerative treatments based on the well-char-742 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.acterized cellular potentials of MSCs suggests that our under-
standing of how even familiar stem cells can be exploited
therapeutically in vivo remains primitive.
MSCs are being tested in a wide range of clinical indications
where the clinical hypotheses are more speculative, the thera-
peutic mechanisms are incompletely defined, and in some
instances the preclinical evidence is highly contentious. For
example, from a scientific foundation that can be traced to
a highly controversial report that whole bone marrow would
regenerate cardiac muscle following transplantation into injured
hearts (Orlic et al., 2001), an observation later disproven (Balsam
et al., 2004), thousands of patients have been treated in trials
worldwide with various cell preparations of bone marrow or
MSCs, with the scientific community debating the significance
of the results (Choi et al., 2011). Subsequent studies have invoked
a variety of contingent mechanisms including salutary paracrine
effects on resident cardiomyocytes and putative cardiac stem
cells, neoangiogenesis, and biomechanical alterations due to
scarring (Gnecchi et al., 2008; Menasche, 2011; Williams et al.,
2011). The questions about underlying mechanism notwith-
standing, combined meta-analyses of numerous trials has
argued for measureable yet quite modest therapeutic effects,
which has left practitioners unsure of the significance and robust-
ness of these therapeutic approaches (Tongers et al., 2011).
MSCs have also been widely tested for their capacity to
mitigate autoimmunity, following somewhat serendipitous
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assays such as mixed lymphocyte reactions and modulate
production and function of the major classes of immune cells
(Kode et al., 2009; Shi et al., 2011). Although it is unclear whether
immune antagonism reflects any native function of MSCs in vivo,
ex vivo expanded preparations have been infused in patients in
hopes of mitigating transplant-related graft versus host disease
and autoimmune conditions like Crohn’s disease, multiple
sclerosis, and systemic lupus (Kebriaei and Robinson, 2011;
Shi et al., 2011). One can find numerous reports of efficacy in
the literature, but these are mixed with negative data (Kebriaei
and Robinson, 2011). The precise role of MSCs as agents for
immune modulation remains to be proven.
When clinical indications stray yet further from the presump-
tive core functions of MSCs, and therapeutic mechanisms
become increasingly speculative, clinical translation is a largely
empirical rather than a rational effort. Likewise, while umbilical
cord blood (UCB) has emerged as a viable alternative to other
sources of HSCs (e.g., mobilized peripheral blood or bone
marrow) for the treatment of leukemia and nonmalignant hema-
tologic conditions (Rocha et al., 2004), it has also become
a common source for experimental interventions in a wide variety
of nonhematologic indications as disparate asmyocardial infarc-
tion, multiple sclerosis, amyotrophic lateral sclerosis, cerebral
palsy, traumatic brain injury, stroke, and inherited metabolic
disorders (Copeland et al., 2009; Harris, 2009; McKenna and
Sheth, 2011; Prasad and Kurtzberg, 2009). Evidence exists
that a number of distinct cell types can be cultured from UCB,
including multipotential stem cells (Ko¨gler et al., 2004; Pelosi
et al., 2012), but it is unclear whether such expandable cell pop-
ulations exist at appreciable levels in unmanipulated samples.
While in theory such cells could mediate therapeutic effects,
nonhematologic indications for UCB transplantation have not
been widely accepted into standard practice. When clinical
investigation proceeds largely empirically, and without a deeper
understanding of the basic therapeutic mechanisms, it is difficult
to reformulate therapeutic strategies after clinical failures.
Neural stem cells (NSC) can be cultured from fetal and adult
brain and demonstrated to differentiate into neurons, oligoden-
drocytes, and astrocytes in vitro. Given the wide array of neuro-
logic conditions that have devastating clinical consequences,
there is considerable interest in the therapeutic potential of
neural regeneration therapies. However, neurodegenerative
diseases, catastrophic stroke, traumatic brain injury, and spinal
paralysis are among the most daunting challenges for regenera-
tive medicine. The development of the brain and peripheral
nerves and their interconnectedness with tissues throughout
the body requires a remarkably complex choreography during
fetal development. The proper milieu for directing the formation
of highly specified neuronal subtypes and guiding their projec-
tion to and interconnectedness with critical targets is highly
unlikely to exist in the adult body. But faced with compelling
unmet medical need and desperation on the part of patients,
there are hundreds of investigator-initiated clinical trials occur-
ring in academic settings (Figure 1), and several companies
have forged efforts to develop novel therapies through intracere-
bral or spinal transplantation of neural stem cells (Trounson et al.,
2011). StemCells Inc (California, USA) has tested NSCs in
Batten’s disease (neuronal ceroid lipofuscinosis) and was ableto document safe delivery but discontinued the trial because of
the inability to accrue an adequate number of patients. Their
current focus is Pelizaeus-Merzbacher disease, a myelin
disorder, and chronic spinal cord injury. Other companies are
testing NSC transplant for stroke (ReNeuron, United Kingdom),
amyotropic lateral sclerosis (Neuralstem, Inc, Maryland, USA),
and Parkinson’s disease (NeuroGeneration, California, USA). In
most of these cases, the clinical hypotheses being tested do
not depend upon the generation of neurons de novo, but instead
on complementation of enzyme deficiencies, remyelination, or
modulation of endogenous repair through neoangiogenesis or
neuroprotection.
Although widely publicized, there are comparatively few clin-
ical trials of products derived from human embryonic stem cells
(hESCs). The first trial conducted in humans delivered oligoden-
drocyte progenitors for the remyelination of spinal cord axons
damaged through crush injury. These studies were based on
extensive preclinical experience with the derivation and charac-
terization of oligodendrocytes and their delivery in animalmodels
that showed remyelination and restoration of motor function
(Keirstead et al., 2005; Liu et al., 2000; McDonald and Belegu,
2006; McDonald and Howard, 2002; McDonald et al., 1999;
Nistor et al., 2005). Moreover, this first trial required a herculean
effort to satisfy FDA regulatory oversight, by report entailing the
submission of over 20,000 pages of data and documentation.
The trial, sponsored by the Geron Corporation (California,
USA), enrolled and treated its first four patients before being dis-
continued due to a decision by company management to focus
on alternative corporate priorities (Baker, 2011). No formal
results have yet been released regarding the phase 1 clinical trial
in this first small cohort of patients, but the primary endpoints
were safety of the cells, and at the very least one hopes that
some evidence will be gleaned that products of ESCs can be
delivered without risk of teratoma, although long-term follow-
up of all treated patients will be necessary.
The only other current clinical trials involve transplantation of
hESC-derived cells to treat retinal blindness. This condition
takes many forms, both genetic and age-related, and as a group
of disorders has many appealing features for stem cell-based
interventions. The retina is accessible for local delivery of cells,
which can then be monitored via direct visualization. The retina
may also provide some degree of immune privilege. Very prelim-
inary results of a trial involving the subretinal injection of hESC-
derived retinal pigment epithelial cells for Stargardt’s macular
degeneration and another for age-related macular degeneration
sponsored by the company Advanced Cell Technologies (ACT)
were recently reported, despite experience on only one patient
in each trail (Schwartz et al., 2012). Only one of the two patients
showed evidence of persistent cells but both were reported to
show some restoration of visual perception. While it is difficult
to draw conclusions from these early trials due to the limited
numbers of patients involved and the very brief 4 month period
of follow-up, the trials represent milestones in that the investiga-
tors succeeded in clearing considerable regulatory hurdles and
met very high standards of preclinical cell characterization and
quality control prior to exposing patients to the risk of ESC-
based products. The experience alone, for both investigators
and regulators, is an essential albeit small step forward in the
long path to establishing ESC-based therapeutics.Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 743
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in the context of numerous clinical trials, yet another arm of
regenerative medicine—tissue engineering—is comingling
MSCs or a variety of other cultured cell types with biocompatible
materials to solve surgical challenges. Reconstruction of blad-
ders (Aboushwareb and Atala, 2008; Atala, 2011; Tian et al.,
2010), tendons (Sun et al., 2011), and complex structures like
the trachea (Macchiarini et al., 2008) represent solutions to
highly personal needs of specific patients and are acceptably
performed as highly innovative and individualized surgical thera-
pies, part of the long tradition of surgical innovation. The mech-
anisms for developing such novel interventions and gaining
acceptance by the surgical and biomedical communities involve
the same core principles required for medical interventions—
sound scientific rationale and methods, institutional and practi-
tioner accountability, thorough and rigorous informed consent,
patient follow-up, timely reporting of adverse events, peer review
of therapeutic claims, and publication in the medical literature.
The potential for therapeutic innovation at the interface of stem
cell biology and tissue engineering is particularly appealing but
beyond the scope of this review. I refer the reader instead to
excellent recent reviews (Griffin et al., 2011; Peck et al., 2012;
Sun et al., 2011).
Anticipated Future Interventions and Opportunities
Among the many disparate conditions, disorders, and diseases
for which stem cells have offered promise, a few stand out as
particularly compelling. In general, they are conditions where
defects are largely cell autonomous and entail the loss or
dysfunction of a single class of cells or a monocellular compo-
nent of a complex tissue, such that restoration of function
through cell replacement would be curative or significantly
ameliorate symptoms. Those conditionsmost amenable to treat-
ment present the least anatomic complexity and affect tissues
that do not typically regenerate spontaneously because they
lack endogenous pools of tissue stem cells. We can predict ulti-
mate success with most confidence if some clinical evidence
already exists that cell replacement might indeed be therapeutic,
for instance through prior assessments of cadaveric or fetal
tissue transplantation. For conditions previously treated with
cadaveric or fetal material, efficacy may be limited by the inade-
quate supply or quality of the cells, making pluripotent or reprog-
rammed cell sources advantageous.
Parkinson’s Disease. Although neurologists recognize that
Parkinson’s disease (PD) has systemic features, the chief deficit
remains the loss of a specific subtype of midbrain dopaminergic
neurons located in a deep brain structure, the substantia nigra,
whose many connections to the striatum are responsible for
regulating movements, such that PD patients suffer from immo-
bility, rigidity, and tremor. Drug replacement with precursors of
dopamine (DA), dopamine agonists, or antagonists of dopamine
metabolism serves to ameliorate symptoms but cannot stem the
inexorable decline in most patients. Based on decades of expe-
rience from several groups with transplantation of fetal tissue
sources of DA neurons, deep brain transplantation can indeed
restore local DA production and ameliorate symptoms, with
some patients showing durable improvement and graft integrity
after two decades (Freed et al., 1992; Lindvall et al., 1990; Lind-
vall et al., 1994; Piccini et al., 1999, 2005). Functional imaging
and postmortem analysis support the stable integration and744 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.persistence of grafts in some patients, prompting continued
enthusiasm for this approach among some practitioners,
provided that a suitable source of DA neurons can be defined
(Freed et al., 1992; Lindvall et al., 1990, 1994; Ma et al., 2010;
Nakamura et al., 2001; Piccini et al., 1999, 2000). Others,
however, remain skeptical, in part because a trial of fetal grafts
randomized against sham surgery was inconclusive, with some
patients sustaining functional decline postsurgery due to dyski-
nesias as a result of excessive graft function (Freed et al.,
2001). Supporters of cell therapy for PD point out that amore reli-
able, consistent, and defined source of DA neurons would justify
further testing of transplantation strategies.
Many groups have differentiated DA neurons from both neural
stem cell and pluripotent stem cell sources and proven func-
tional in rodent models (Hargus et al., 2010; Sanchez-Pernaute
et al., 2008; Tabar et al., 2008; Wernig et al., 2008). Analysis
of this DA neuron production has not always distinguished
among the many different classes of neurons that produce DA
throughout the neuraxis, but recent advances have made
possible the differentiation from pluripotent cell sources of
regionally specific midbrain DA neuronal subtypes whose defi-
ciency is most affected in PD is possible, and such cells have
been documented to function in rodent and primate models
(Chambers et al., 2009; Fasano et al., 2010; Kriks et al., 2011).
Moreover, techniques for producing personalized autologous
stem cells via somatic cell reprogramming now exist, and it
has been shown that autologous cells function better than cells
derived from unrelated donors in rodent models of PD transplant
(Tabar et al., 2008). The availability of highly specified, defined,
autologous DA neuron preparations creates legitimate opportu-
nities for testing in PD patients, including the testing of specific
doses to establish a dose-response curve. Nevertheless, even
optimistic accounts identify the significant hurdles that remain
(Lindvall and Kokaia, 2010). Notably, any cell therapy must ulti-
mately be superior in safety and efficacy to any drug therapy,
and establishing such utility will require large-scale and pains-
taking prospective trials to be conducted over many years.
Thus, despite promise, cell therapy as the standard of care for
PD is but a distant horizon.
Cell therapy for PD will need to be efficacious and safe to
compete with the highly effective drug treatments that currently
exist (Hjelmgren et al., 2006). In contrast, a condition like
Huntington’s disease, which has no viable drug therapy and is
invariably fatal, is an appealing alternative therapeutic target
for cell transplantation therapies derived from NSCs and ESCs.
Intrastriatal transplantation of homotypic fetal tissues has shown
graft durability and reports of amelioration of symptoms in HD
patients (Gallina et al., 2010; Nicoleau et al., 2011). As for PD,
an improved cell source would facilitate the necessary studies
to optimize the dose and target region for cell transplantation.
Techniques for directed differentiation of ESCs into relevant
medium spiny neurons and amelioration of rodent models of
HD have been reported and bode well for future translational
clinical studies (Benraiss and Goldman, 2011).
Autoimmune Diabetes Mellitus. Type 1 diabetes (T1D; insulin-
dependent, juvenile onset) is an autoimmune condition that
involves active immune destruction of the beta cells of the islets
of Langerhans of the pancreas, leaving the patient with inade-
quate supplies of insulin and susceptibility to hyperglycemic
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nosis, patients harbor depleted pools of beta cells and are
unable to mount a regenerative response to restore beta cell
mass, even if their autoimmune response can be controlled.
Whether beta cells regenerate after injury in the adult pancreas
has been vigorously debated (Bonner-Weir and Weir, 2005;
Dor et al., 2004; Dor and Melton, 2008), but endogenous regen-
eration under pathologic conditions is not robust, and alternative
sources of beta cells would therefore be required. Deriving fully
functional beta cells in vitro from pluripotent stem cells has
proved challenging, but a group from the biotechnology
companyNovocell did report successful derivation of precursors
in vitro that appear to fully differentiate and mature after trans-
plantation in vivo (D’Amour et al., 2006; Kroon et al., 2008). In
a more recent advance, Gadue and colleagues have derived
a stably expandable endodermal progenitor that is more efficient
at producing beta cells than if one proceeds directly from ESC
(Cheng et al., 2012). If a reliable source of beta cells can be
produced in vitro, a credible path toward clinical development
could be envisioned. We know that transplantation of whole
pancreas, or infusion of islet preparations from cadaveric sour-
ces in the context of a corticosteroid-sparing regimen of immune
suppression (the ‘‘Edmondton Protocol’’), can restore glycemic
control for extended time periods (Shapiro et al., 2000, 2006).
Although patients later relapse, the potential for repeated cell
infusions would be greatly facilitated by a more abundant source
of beta cells, and deriving purified beta cells from pluripotent
stem cell sources thus remains a much sought after goal in
stem cell biology. As T1D is an autoimmune disorder, it seems
unlikely that autologous cells would be a preferable source of
material to allogeneic cells, as immune suppression to protect
the beta cells would still be required in either scenario. Attempts
to convert exocrine pancreatic tissue into beta-like endocrine
cells through ectopic expression of transcription factors, a type
of direct reprogramming of cell fates in situ, is a new therapeutic
concept with provocative appeal (Zhou et al., 2008).
Other Treatable Conditions on the Horizon. Corneal injury that
leads to scarring and blindness has prompted efforts to culture
and expand limbal stem cells into corneal patches in vitro, fol-
lowed by corneal grafting. Recent reports confirm several inde-
pendent studies that corneal grafting using alternative sources
of epithelial cells can restore vision, and appears to be a prom-
ising novel stem cell-based treatment for a grave but rare human
condition (Nishida et al., 2004; Rama et al., 2010; Tsai et al.,
2000; Tsubota et al., 1999). Liver transplantation cannot meet
the demands of patients suffering from liver failure around the
globe, and production of hepatocyte-like cells from pluripotent
stem cells sources has been reported by several groups. Despite
considerable similarity to native hepatocytes, the in vitro derived
cells have not yet been reported to be fully functional in animal
models, and considerable challenges remain for achieving func-
tional integration of in vitro derived hepatocytes, especially for
conditions like cirrhosis that already entail markedly altered liver
anatomy and compromised circulation. Similarly, production of
cardiomyocytes appears to be robust in the petri dish, but
achieving engraftment in the damaged heart of a clinically mean-
ingful dose of cells, together with integration in a manner that
restores pump function, remains a major challenge. In this
case, clever engineering of biomaterials might enable the crea-tion of contractile cardiac patches that could be sewn onto the
heart. Finally, producing HSCs from personalized pluripotent
stem cells, coupled to gene repair, is an appealing strategy for
dozens of genetic disorders of the bone marrow including
immune deficiency, hemoglobinopathy, and genetic marrow
failure syndromes. Still other potential indications for tissue
replacement therapies involve in vitro production of endothelial
cells and potentially even human gametes, but none appear to
have imminent clinical application. All cell replacement therapies
face similar challenges of graft integration into the host environ-
ment, which entails trafficking, homing, and integration into
native niches or microenvironments, connection to a host blood
supply, immune compatibility, and graft durability. Solving such
challenges will engage the research community for decades to
come.
Who Will Translate Stem Cell Science into Regenerative
Medicine?
Scientific advances in stem cell biology are being driven by the
current intellectual ferment and excitement of the field, but
when and how these advances will be translated into successful
treatments remain fertile questions for debate. Will cell therapies
remain a highly patient-focused endeavor performed solely in
academic medical centers, akin to bone marrow or solid organ
transplantation? Or will stem cells ever become commercial,
pharmaceutical grade ‘‘off-the-shelf’’ products?
One might imagine a future in which medical centers offer
highly customized, patient-focused approaches to stem cell
treatments, perhaps utilizing the products of personalized
induced pluripotent stem cells (see Yamanaka, 2012, this issue).
IPS cells have enormous theoretical appeal as vehicles for
combined gene repair and cell replacement therapy for genetic
disease (Daley and Scadden, 2008). Newer forms of stem cell
transplant could replicate the current status of bone marrow
transplantation, which has developed into a remarkably complex
infrastructure for capturing cellular and molecular information in
international registries for literally millions of potential donors and
entails lengthy, costly, and risky interventions in intensive clinical
care settings. Given the imperative of treating patients in need,
stem cell transplants for genetic and acquired diseases will
emerge from academic centers because clinician investigators
will develop them and patients will demand them. Like gene
repair (‘‘gene therapy’’), cell replacement therapies will probably
serve rare conditions first and pertain to small numbers of
patients receiving highly individualized treatments, perhaps
coupling gene repair with autologous cell replacement ap-
proaches, for example for blood diseases. Such small-scale
applications will dominate until and unless generic interventions
and off-the-shelf approaches prove feasible.
The prospects for more widespread stem cell-based treat-
ments depends on either solving the immune rejection barrier,
through advances in promoting immune tolerance to allogeneic
tissues, or accepting the use of immune suppression—even life-
long—to facilitate allogeneic cell therapies. Immune suppression
is already standard for organ transplantation, so we know that its
use to facilitate life-sustaining cell therapy is feasible. Because
cell manufacture is likely to be the most costly and time-
consuming aspect limiting cell therapies, the prospects for
realizing economies of scale would seem to call for the establish-
ment of master cell banks that could be the source of cellsCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 745
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and the resulting variety of tissue types is far too great in human
populations to expect banks to be able to supply perfect tissue
matches for all potential patients. Instead, one might envision
banks of cells derived from donors with highly common geno-
types of the histocompatibility genes. This type of approach
would be greatly facilitated by cell strains with homozygosity of
histocompatibility loci. Past approximations of the number of
cell lines that would be needed in such a repository or master
cell bank, based on modeling data from pools of kidney trans-
plant patients and recipients in the United Kingdom and Japan,
have suggested that a bank comprised on the order of 10–50
cell lines might effectively provide a single HLA antigen match
(deemed aminimal requirement for acceptable solid organ trans-
plantation) for approximately 80% of the local population (Gour-
raud et al., 2012; Nakajima et al., 2007; Taylor et al., 2011, 2005).
While encouraging, these numbers suggest that some kind of
dual system might well be needed in which the vast majority of
individuals can benefit from off-the-shelf therapies, but person-
alized autologous cells derived via reprogramming would be
needed for those with difficult-to-match tissue types.
Alternatives to Cell Therapy
Because of the significant hurdles that remain in terms of cell
manufacture, delivery, anatomical integration, and immune
suppression for all but highly personalized therapies, it is entirely
possible that more traditional modes of treatment will evolve
from stem cell research and ultimately prove the most feasible.
Indeed, the generation of patient-derived stem cells holds the
most immediate promise for advancing traditional drug
discovery paradigms (for a recent review, see Grskovic et al.,
2011). Capturing diseases in a dish promises to enable cell-
based phenotypic assays that could yield new drugs that repair
cell and tissue defects, or perhaps act on endogenous pools of
stem cells, stimulating repair and regeneration. For tissues that
do not readily regenerate from endogenous pools of stem cells,
such as the majority of the brain, the heart, and the kidney,
another provocative possibility is the direct conversion of one
cell or tissue identity to another that has been depleted by
disease or injury. A host of such conversions have been realized
in vitro, converting fibroblasts into cells that resemble and exhibit
some functions like neurons, cardiomyocytes, and hepatocytes
(Vierbuchen and Wernig, 2011). Cell conversion has consider-
able theoretical advantages, but whether this new cellular
alchemy can be harnessed for therapeutic end remains almost
science fiction at present, although it is clearly worthy of deeper
exploration.
Threats to Clinical Translation and to the Integrity
of Regenerative Medicine
Translating the basic discoveries of stem cell biology into robust,
effective, and safe new modalities of care will mean solving new
challenges; before success, regenerative medicine will suffer
many setbacks. While translating too timidly might deprive
needy patients of precious time and life quality, testing cells in
patients before a deeper understanding of how stem cells
work is risky, too. We need to be confident that we understand
the full spectrum of safety concerns and can therefore avoid
placing patients at undue risk. We also need to design rigorous,
blinded, and when possible randomized trials where evidence
for clinical efficacy can be defined precisely, rather than depend746 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.upon anecdote and clinical observation alone. Given that
patients and practitioners may carry unrealistic expectations of
clinical efficacy, there is a high likelihood for a robust placebo
effect as well as interpretive bias in reporting of clinical results.
We also need to be conscious of not exhausting resources that
would be better spent on more practical health care needs.
Premature application runs the risk of high-profile failure that
would sully the credibility of this still-developing field.
With the goal of advancing clinical investigation while
preserving rigor, promoting medical innovation while protecting
patients, and ensuring integrity in regenerative medicine while
respecting autonomy of individual practitioners and patients,
the International Society for Stem Cell Research (ISSCR) assem-
bled an international group of scientists, surgeons, gene
therapists, bioethicists, patient advocates, and attorneys and
composed ‘‘The ISSCR Guidelines for the Clinical Translation
of Stem Cells’’ (Hyun et al., 2008). These guidelines articulated
principles and standards as a roadmap for practitioners and
regulatory bodies when considering if, when, and how to allow
tests of experimental stem cell therapies in actual patients. The
guidelines call for independent and rigorous analysis of the deci-
sion to test novel treatments in patients, by reviewers with rele-
vant area-specific expertise, who are free of conflicts of interest
that might lead to positive or negative bias. Expert judgment
about the reliability and rigor of the preclinical evidence for effi-
cacy and safety of cellular products is essential for weighing
the potential risks against the potential benefits before launching
a clinical trial.
Because no preclinical animal or cellular model is entirely
predictive of outcomes in patients, a credible and rigorous
process of informed consent is essential to protecting the
autonomy of patients and their thoughtful engagement in the
research process, where they consent to participate without
heightened expectations or therapeutic misconception; such
wishful thinking renders patients vulnerable to exploitation and
contaminates interpretations of therapeutic efficacy.
Medical Innovations outside of Clinical Trials
Many in the medical field recognize the value of innovation
outside the context of a clinical trial. However, especially if incor-
porating the use of highly manipulated cell preparations, such
innovative attempts at therapy in the United States should fall
under the jurisdiction of the Food and Drug Administration. To
comply with accepted professional standards governing the
practice of medicine, highly novel uses of any cellular product
should not be performed on more than a small number of
patients before such use is subject to independent review of
the scientific rationale, informed consent, close patient follow-
up, and reporting of adverse events. Any attempt to extend the
innovative therapy to a larger group of patients should be
preceded by a standard clinical trial. Although some may
contend that requiring approval for the practice of novel clinical
treatments from an independent body undermines the autonomy
of practitioners to provide care to their patients, independent
peer review ensures that the rationale for treatment is sound
and represents a defensible community standard of medical
practice.
Premature Clinical Translation
The traditional strategy for proving that a medical intervention
works and is safe requires rigorous clinical trial design, can be
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highly organized medical settings. However, the history of even
legitimate medical practice is rife with examples of instances
whereby trust in medical intuition alone, or reliance on uncon-
trolled retrospective or purely observational studies, has led to
mistaken presumptions about medical efficacy, only to be cor-
rected when rigorous blinded, randomized trials proved our
presumptions to be false (for example, high-dose chemotherapy
and autologous marrow rescue for metastatic breast cancer,
postmenopausal hormone replacement therapy and cardiovas-
cular risk, to name just two).
The fledgling field of stem cells is already suffering from the
taint of illegitimate clinical translation. A quick Google search
for ‘‘stem cell treatments’’ returns a plethora of sponsored
websites peddling cures for ailments as diverse as Alzheimer’s
disease andautism.AsdocumentedbyCaulfield andcolleagues,
such websites systematically overpromise the potential efficacy
of stem cells and trivialize the potential risks (Lau et al., 2008).
Sadly, even sophisticated patients or their families can bemisled
by the veneer of scientific credibility on such websites.
As stated previously, apart from treatments using HSCs for
blood diseases, and various dermal and corneal indications,
essentially all other treatments based on stem cells must be
considered experimental medical research and should be
administered exclusively in organized clinical trials. Subjects in
medical research are generally not required to pay for unproven
interventions.
Administering interventions outside of controlled clinical trials
threatens patients and jeopardizes the integrity of and public
trust in medical research, compromising legitimate efforts to
advance knowledge. Because of the particular vulnerabilities of
patients, many governments have enacted laws to protect
patients from exploitation and risk, but some practitioners see
such regulation as burdensome and unwarranted restraints on
their trade. The threat of litigation for medical malpractice serves
as an additional constraint on unwarranted medical practice.
Recently, the German government shut down the Xcell Clinic
when a child died after receiving intracranial injections of cord
blood in an unproven intervention. A recent report documented
the development of glioneural masses in the brain and spinal
cord of a child who was treated with intrathecal infusions of
what were reportedly neural stem cells for ataxia telangectasia,
a genetic movement disorder (Amariglio et al., 2009). While
one hopes that most stem cell interventions are benign, the
safety data are still rudimentary.
The history of ‘‘gene therapy’’ was shaped in a deleterious way
by the untimely death of a young man, Jesse Gelsinger, in an
FDA-approved clinical study. James Wilson, the physician
responsible for the gene therapy clinical trial in question, has
written a compelling admonition to practitioners of stem cell
therapies, warning that much of the history that prompted
premature clinical translation of gene therapy is being repeated
by the practitioners of stem cell therapy (Wilson, 2009). He
sees the same assumptions of a ‘‘simplistic, theoretical model
indicating that the approach ‘‘ought to work’’; ‘‘a large popula-
tion of patients with disabling or lethal diseases . harboring
fervent hopes’’; and ‘‘unbridled enthusiasm of some scientists
in the field, fueled by uncritical media coverage.’’ He ends
with, ‘‘I am concerned that expectations for the timeline andscope of clinical utility of hESCs have outpaced the field’s actual
state of development and threaten to undermine its success.’’
The warning is just as appropriate for all kinds of stem cells—
umbilical cord blood, neural stem cell, mesenchymal stem cells.
Conclusions
The maturation of new therapeutics takes decades. If one exam-
ines the history of any of the recent new thrusts in biomedicine—
recombinant DNA, monoclonal antibodies, gene therapy, or
RNAi—the vanguard treatments were introduced within
a decade but 20 years passed before the full impact of the
new form of medicine was felt widely in clinical medicine; for
RNAi, we are still waiting for clinical success. Fifty years after
the first attempts at HSC transplantation, and even with all the
improved understanding we now have of both HSCs and
immunological mismatch, our success rates are still woefully
inadequate. Although the development of novel stem cell-based
therapies will benefit greatly from the collective failures and
acquired experience of marrow transplantation, our ignorance
of the challenges of applying stem cells in distinct tissues with
far greater anatomic complexity than the blood should give us
pause as practitioners and inspire humility. Realistically, we
should anticipate that new therapies based on stem cells for
other tissues will likewise take decades to mature. In the short
term, there will probably be more failures than successes, and
one can only hope that the new field of regenerative medicine
can learn the lessons of the past and proceed with prudence
and caution.
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